Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has said that the FDA has approved the use of Nexium in children ages one to 11 years old for the short-term treatment of gastroesophageal reflux disease or GERD for up to eight weeks.
Subscribe to our email newsletter
The FDA has also approved a new 10mg dose formulation of Nexium for delayed-release oral suspension for use in children one to 11 years old and the product will be available later this year.
Marta Illueca, Nexium brand medical director, AstraZeneca Pharmaceuticals US, said: “This dosing alternative of Nexium for oral suspension allows patients, such as children and the elderly, who are unable to swallow capsules or tablets to have an alternative treatment option for controlling their GERD.”